{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:24:21Z","timestamp":1782739461708,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.clgc.2018.05.011","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T12:53:05Z","timestamp":1527079985000},"page":"e997-e1002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non\u2013clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus"],"prefix":"10.1016","volume":"16","author":[{"given":"Inkeun","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Lyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2018.05.011_bib1","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clgc.2018.05.011_bib2","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.05.011_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.05.011_bib4","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2018.05.011_bib5","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.05.011_bib6","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.05.011_bib7","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.05.011_bib9","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2018.05.011_bib10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12032-009-9177-0","article-title":"Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies","volume":"26","author":"Dutcher","year":"2009","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(09)70162-7","article-title":"Safety and efficacy of sunitinib for metastatic renal cell carcinoma: an expanded-access trial","volume":"10","author":"Gore","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib13","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1093\/annonc\/mdr586","article-title":"Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma","volume":"23","author":"Lee","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10637-010-9491-6","article-title":"Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma","volume":"30","author":"Molina","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clgc.2018.05.011_bib15","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdv149","article-title":"First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG).\u2020","volume":"26","author":"Ravaud","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.eururo.2012.06.043","article-title":"A\u00a0phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma","volume":"62","author":"Tannir","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2018.05.011_bib17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib18","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2018.05.011_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fonc.2012.00013","article-title":"Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma","volume":"2","author":"Bukowski","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib20","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.05.011_bib21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00432-013-1386-4","article-title":"Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component","volume":"139","author":"Park","year":"2013","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib22","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2013.54.6911","article-title":"Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma","volume":"32","author":"Motzer","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib23","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","article-title":"A\u00a0systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma","volume":"71","author":"Fernandez-Pello","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2018.05.011_bib24","doi-asserted-by":"crossref","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib25","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Kidney Cancer (Version 4.2018). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf. Accessed: June 7, 2018."},{"key":"10.1016\/j.clgc.2018.05.011_bib26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4143\/crt.2016.584","article-title":"Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter, phase II study","volume":"50","author":"Jung","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clgc.2018.05.011_bib27","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1200\/JCO.2016.67.9084","article-title":"Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma","volume":"34","author":"Voss","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40425-018-0319-9","article-title":"Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma","volume":"6","author":"Koshkin","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clgc.2018.05.011_bib29","article-title":"Clinical activity of PD1\/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC)","author":"Moreira","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clgc.2018.05.011_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","author":"Cancer Genome Atlas Research Network","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.05.011_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ccr.2014.07.014","article-title":"The somatic genomic landscape of chromophobe renal cell carcinoma","volume":"26","author":"Davis","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2018.05.011_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ng.3146","article-title":"Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes","volume":"47","author":"Durinck","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clgc.2018.05.011_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2018.05.011_bib34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.05.011_bib35","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.2017.72.2967","article-title":"Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer","volume":"35","author":"Choueiri","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318301496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318301496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:30:23Z","timestamp":1761564623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318301496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1558767318301496"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.05.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non\u2013clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}